ENTRY ko05165 Pathway NAME Human papillomavirus infection DESCRIPTION Human papillomavirus (HPV) is a non-enveloped, double-stranded DNA virus. HPV infect mucoal and cutaneous epithelium resulting in several types of pathologies, most notably, cervical cancer. All types of HPV share a common genomic structure and encode eight proteins: E1, E2, E4, E5, E6, and E7 (early) and L1 and L2 (late). It has been demonstrated that E1 and E2 are involved in viral transcription and replication. The functions of the E4 protein is not yet fully understood. E5, E6, and E7 act as oncoproteins. E5 inhibits the V-ATPase, prolonging EGFR signaling and thereby promoting cell proliferation. The expression of E6 and E7 not only inhibits the tumor suppressors p53 and Rb, but also alters additional signalling pathways. Among these pathways, PI3K/Akt signalling cascade plays a very important role in HPV-induced carcinogenesis. The L1 and L2 proteins form icosahedral capsids for progeny virion generation. CLASS Human Diseases; Infectious disease: viral PATHWAY_MAP ko05165 Human papillomavirus infection DRUG D02783 Afovirsen sodium (USAN) D06555 Amolimogene bepiplasmid (USAN) D06666 Verpasep caltespen (USAN/INN) D13165 Zopapogene imadenovec (USAN/INN) ORTHOLOGY K00182 WNT2; wingless-type MMTV integration site family, member 2 K00312 WNT3; wingless-type MMTV integration site family, member 3 K00408 WNT4; wingless-type MMTV integration site family, member 4 K00444 WNT5; wingless-type MMTV integration site family, member 5 K00445 WNT6; wingless-type MMTV integration site family, member 6 K00572 WNT7; wingless-type MMTV integration site family, member 7 K00714 WNT8; wingless-type MMTV integration site family, member 8 K00873 PK, pyk; pyruvate kinase [EC:2.7.1.40] K00922 PIK3CA_B_D; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta [EC:2.7.1.153] K01064 WNT9; wingless-type MMTV integration site family, member 9 K01110 PTEN; phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [EC:3.1.3.16 3.1.3.48 3.1.3.67] K01357 WNT10; wingless-type MMTV integration site family, member 10 K01384 WNT11; wingless-type MMTV integration site family, member 11 K01558 WNT16; wingless-type MMTV integration site family, member 16 K02085 APC; adenomatosis polyposis coli protein K02089 CDK4; cyclin-dependent kinase 4 [EC:2.7.11.22] K02091 CDK6; cyclin-dependent kinase 6 [EC:2.7.11.22] K02105 CTNNB1; catenin beta 1 K02144 ATPeV1H; V-type H+-transporting ATPase subunit H K02145 ATPeV1A, ATP6A; V-type H+-transporting ATPase subunit A [EC:7.1.2.2] K02146 ATPeV0D, ATP6D; V-type H+-transporting ATPase subunit d K02147 ATPeV1B, ATP6B; V-type H+-transporting ATPase subunit B K02148 ATPeV1C, ATP6C; V-type H+-transporting ATPase subunit C K02149 ATPeV1D, ATP6M; V-type H+-transporting ATPase subunit D K02150 ATPeV1E, ATP6E; V-type H+-transporting ATPase subunit E K02151 ATPeV1F, ATP6S14; V-type H+-transporting ATPase subunit F K02152 ATPeV1G, ATP6G; V-type H+-transporting ATPase subunit G K02153 ATPeV0E, ATP6H; V-type H+-transporting ATPase subunit e K02154 ATPeV0A, ATP6N; V-type H+-transporting ATPase subunit a K02155 ATPeV0C, ATP6L; V-type H+-transporting ATPase 16kDa proteolipid subunit K02157 AXIN1; axin 1 K02158 BAD; Bcl-2-antagonist of cell death K02159 BAX; apoptosis regulator BAX K02187 CASP3; caspase 3 [EC:3.4.22.56] K02206 CDK2; cyclin-dependent kinase 2 [EC:2.7.11.22] K02235 FZD2; frizzled 2 K02329 FZD3; frizzled 3 K02353 DVL; segment polarity protein dishevelled K02354 FZD4, fz4, CD344; frizzled 4 K02373 FADD; FAS-associated death domain protein K02375 FZD5_8, fz2; frizzled 5/8 K02376 FZD6; frizzled 6 K02432 FZD1_7, fz; frizzled 1/7 K02580 NFKB1; nuclear factor NF-kappa-B p105 subunit K02599 NOTCH1; Notch 1 K02620 TCF7, TCF-1; transcription factor 7 K02649 PIK3R1_2_3; phosphoinositide-3-kinase regulatory subunit alpha/beta/delta K02833 HRAS; GTPase HRas K02842 FZD9_10, CD349_50; frizzled 9/10 K03062 PSMC1, RPT2; 26S proteasome regulatory subunit T2 K03083 GSK3B; glycogen synthase kinase 3 beta [EC:2.7.11.26] K03099 SOS; son of sevenless K03120 TBP; transcription initiation factor TFIID TATA-box-binding protein K03156 TNF, TNFA; tumor necrosis factor superfamily, member 2 K03158 TNFRSF1A, TNFR1, CD120a; tumor necrosis factor receptor superfamily member 1A K03171 TRADD; tumor necrosis factor receptor type 1-associated DEATH domain protein K03174 TRAF3; TNF receptor-associated factor 3 K03209 WNT1; wingless-type MMTV integration site family, member 1 K03456 PPP2R1; serine/threonine-protein phosphatase 2A regulatory subunit A K03661 ATPeV0B, ATP6F; V-type H+-transporting ATPase 21kDa proteolipid subunit K03662 ATPeVS1, ATP6S1; V-type H+-transporting ATPase S1 subunit K03900 VWF; von Willebrand factor K04237 PARD3; partitioning defective protein 3 K04261 PTGER4; prostaglandin E receptor 4 K04345 PKA; protein kinase A [EC:2.7.11.11] K04354 PPP2R2; serine/threonine-protein phosphatase 2A regulatory subunit B K04357 EGF; epidermal growth factor K04361 EGFR, ERBB1; epidermal growth factor receptor [EC:2.7.10.1] K04364 GRB2; growth factor receptor-bound protein 2 K04366 RAF1; RAF proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1] K04368 MAP2K1, MEK1; mitogen-activated protein kinase kinase 1 [EC:2.7.12.2] K04369 MAP2K2, MEK2; mitogen-activated protein kinase kinase 2 [EC:2.7.12.2] K04371 ERK, MAPK1_3; mitogen-activated protein kinase 1/3 [EC:2.7.11.24] K04382 PPP2C; serine/threonine-protein phosphatase 2A catalytic subunit [EC:3.1.3.16] K04385 AXIN2; axin 2 K04389 TNFSF6, FASL, CD178; tumor necrosis factor ligand superfamily member 6 K04390 TNFRSF6, FAS, CD95; tumor necrosis factor receptor superfamily member 6 K04393 CDC42; cell division control protein 42 K04398 CASP8; caspase 8 [EC:3.4.22.61] K04451 TP53, P53; tumor protein p53 K04456 AKT; RAC serine/threonine-protein kinase [EC:2.7.11.1] K04467 IKBKA, IKKA, CHUK; inhibitor of nuclear factor kappa-B kinase subunit alpha [EC:2.7.11.10] K04490 TCF7L1; transcription factor 7-like 1 K04491 TCF7L2; transcription factor 7-like 2 K04498 EP300, CREBBP, KAT3; E1A/CREB-binding protein [EC:2.3.1.48] K04503 CCND1; G1/S-specific cyclin-D1 K04505 PSEN1, PS1; presenilin 1 [EC:3.4.23.-] K04632 GNAS; guanine nucleotide-binding protein G(s) subunit alpha K04659 THBS2S; thrombospondin 2/3/4/5 K04681 RBL1; retinoblastoma-like protein 1 K04688 RPS6KB; ribosomal protein S6 kinase beta [EC:2.7.11.1] K04693 IRF9, ISGF3G, P48; interferon regulatory factor 9 K04728 ATM, TEL1; serine-protein kinase ATM [EC:2.7.11.1] K04735 RELA; transcription factor p65 K05089 PDGFRB, CD140B; platelet-derived growth factor receptor beta [EC:2.7.10.1] K05130 IFNAR1; interferon receptor 1 K05131 IFNAR2; interferon receptor 2 K05401 TLR3, CD283; toll-like receptor 3 K05410 TBK1; TANK-binding kinase 1 [EC:2.7.11.10] K05411 IRF3; interferon regulatory factor 3 K05414 IFNA; interferon alpha K05415 IFNB; interferon beta K05448 VEGFA; vascular endothelial growth factor A K05631 AIP3, WWP3, BAIAP1; atrophin-1 interacting protein 3 (BAI1-associated protein 1) K05635 LAMC1; laminin, gamma 1 K05636 LAMB1; laminin, beta 1 K05637 LAMA1_2; laminin, alpha 1/2 K05717 FN1; fibronectin 1 K05719 ITGB1, CD29; integrin beta 1 K05725 PTK2, FAK; focal adhesion kinase 1 [EC:2.7.10.2] K05760 PXN; paxillin K05842 TRIF; toll-like receptor adapter molecule 1 K05870 CREB1; cyclic AMP-responsive element-binding protein 1 K05948 FNG; fringe [EC:2.4.1.222] K06052 JAG1, CD339; jagged-1 K06053 RBPSUH, RBPJK; recombining binding protein suppressor of hairless K06054 HES1; hairy and enhancer of split 1 K06055 HES5; hairy and enhancer of split 5 K06061 MAML; mastermind K06067 HDAC1_2; histone deacetylase 1/2 [EC:3.5.1.98] K06069 PRKCI; atypical protein kinase C iota type [EC:2.7.11.13] K06090 CRB3; crumbs 3 K06091 MPP5, PALS1; MAGUK p55 subfamily member 5 K06092 INADL, PATJ; InaD-like protein K06093 PARD6; partitioning defective protein 6 K06094 LLGL; lethal(2) giant larvae protein K06236 COL1A; collagen type I alpha K06237 COL4A; collagen type IV alpha K06238 COL6A; collagen type VI alpha K06240 LAMA3_5; laminin, alpha 3/5 K06241 LAMA4; laminin, alpha 4 K06243 LAMB2; laminin, beta 2 K06244 LAMB3; laminin, beta 3 K06245 LAMB4; laminin, beta 4 K06246 LAMC2; laminin, gamma 2 K06247 LAMC3; laminin, gamma 3 K06248 CHAD; chondroadherin K06249 RELN; reelin [EC:3.4.21.-] K06250 SPP1, BNSP, OPN; secreted phosphoprotein 1 K06251 VTN; vitronectin K06252 TN; tenascin K06253 IBSP; integrin binding sialoprotein K06476 ITGA2B, CD41; integrin alpha 2B K06480 ITGA1, CD49a; integrin alpha 1 K06481 ITGA2, CD49b; integrin alpha 2 K06482 ITGA3, CD49c; integrin alpha 3 K06483 ITGA4, CD49d; integrin alpha 4 K06484 ITGA5, CD49e; integrin alpha 5 K06485 ITGA6, CD49f; integrin alpha 6 K06487 ITGAV, CD51; integrin alpha V K06493 ITGB3, CD61; integrin beta 3 K06525 ITGB4, CD104; integrin beta 4 K06583 ITGA7; integrin alpha 7 K06584 ITGA8; integrin alpha 8 K06585 ITGA9; integrin alpha 9 K06586 ITGA10; integrin alpha 10 K06587 ITGA11; integrin alpha 11 K06588 ITGB5; integrin beta 5 K06589 ITGB6; integrin beta 6 K06590 ITGB7; integrin beta 7 K06591 ITGB8; integrin beta 8 K06618 RB1; retinoblastoma-associated protein K06624 CDKN1B, P27, KIP1; cyclin-dependent kinase inhibitor 1B K06625 CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A K06626 CCNE; G1/S-specific cyclin-E1 K06627 CCNA; cyclin-A K06640 ATR; serine/threonine-protein kinase ATR [EC:2.7.11.1] K06643 MDM2; E3 ubiquitin-protein ligase Mdm2 [EC:2.3.2.27] K06751 MHC1; MHC class I antigen K07201 FOXO1; forkhead box protein O1 K07203 MTOR, FRAP, TOR; serine/threonine-protein kinase mTOR [EC:2.7.11.1] K07205 EIF4EBP1; eukaryotic translation initiation factor 4E binding protein 1 K07206 TSC1; tuberous sclerosis 1 K07207 TSC2; tuberous sclerosis 2 K07208 RHEB; Ras homolog enriched in brain K07209 IKBKB, IKKB; inhibitor of nuclear factor kappa-B kinase subunit beta [EC:2.7.11.10] K07210 IKBKG, IKKG, NEMO; inhibitor of nuclear factor kappa-B kinase subunit gamma K07211 IKBKE, IKKE; inhibitor of nuclear factor kappa-B kinase subunit epsilon [EC:2.7.11.10] K07827 KRAS, KRAS2; GTPase KRas K07828 NRAS; GTPase NRas K08131 COL9A; collagen type IX alpha K08957 CSNK1A; casein kinase 1, alpha [EC:2.7.11.1] K09047 CREB5, CREBPA; cyclic AMP-responsive element-binding protein 5 K09048 CREB3; cyclic AMP-responsive element-binding protein 3 K09087 HES2_6_7; hairy and enhancer of split 2/6/7 K09088 HES3; hairy and enhancer of split 3 K09089 HES4; hairy and enhancer of split 4 K09091 HEY; hairy and enhancer of split related with YRPW motif K09444 IRF1; interferon regulatory factor 1 K10151 CCND2; G1/S-specific cyclin-D2 K10152 CCND3; G1/S-specific cyclin-D3 K10389 TUBG; tubulin gamma K10587 UBE3A, E6AP; ubiquitin-protein ligase E3 A [EC:2.3.2.26] K10691 UBR4, ZUBR1; E3 ubiquitin-protein ligase UBR4 [EC:2.3.2.27] K11126 TERT, EST2; telomerase reverse transcriptase [EC:2.7.7.49] K11217 JAK1; Janus kinase 1 [EC:2.7.10.2] K11219 TYK2; non-receptor tyrosine-protein kinase TYK2 [EC:2.7.10.2] K11220 STAT1; signal transducer and activator of transcription 1 K11221 STAT2; signal transducer and activator of transcription 2 K11315 TADA3, ADA3, NGG1; transcriptional adapter 3 K11583 PPP2R3; serine/threonine-protein phosphatase 2A regulatory subunit B'' K11584 PPP2R5; serine/threonine-protein phosphatase 2A regulatory subunit B' K11643 CHD4, MI2B; chromodomain-helicase-DNA-binding protein 4 [EC:5.6.2.-] K11987 PTGS2, COX2; prostaglandin-endoperoxide synthase 2 [EC:1.14.99.1] K12075 DLG2; discs large protein 2 K12076 DLG1; disks large protein 1 K12159 ISG15; ubiquitin cross-reactive protein K12236 NFX1; transcriptional repressor NF-X1 K13365 SLC9A3R1, NHERF1; sodium/hydrogen exchange regulatory cofactor NHE-RF1 K14009 BCAP31, BAP31; B-cell receptor-associated protein 31 K14021 BAK, BAK1; Bcl-2 homologous antagonist/killer K14608 OASL; 2'-5'-oligoadenylate synthase-like protein K14754 MX; interferon-induced GTP-binding protein Mx K16175 SCRIB; protein scribble K16195 EIF2AK2; eukaryotic translation initiation factor 2-alpha kinase 2 [EC:2.7.11.1] K16332 RBL2; retinoblastoma-like protein 2 K16857 THBS1; thrombospondin 1 K17454 E2F1; transcription factor E2F1 K18952 PRKCZ; atypical protein kinase C zeta type [EC:2.7.11.13] K19260 L1; Papillomaviridae major capsid protein L1 K19719 COL2A; collagen type II alpha K20994 NOTCH2; Notch 2 K20995 NOTCH3; Notch 3 K20996 NOTCH4; Notch 4 K21098 DLG3; discs large protein 3 K21807 E6; Alphapapillomavirus protein E6 K21808 L2; Alphapapillomavirus minor capsid protein L2 K21809 E7; Alphapapillomavirus protein E7 K21810 E1; Alphapapillomavirus replication protein E1 [EC:5.6.2.-] K21811 E2; Alphapapillomavirus regulatory protein E2 K21812 E5; Alphapapillomavirus protein E5 COMPOUND C00575 3',5'-Cyclic AMP C00584 Prostaglandin E2 C05981 Phosphatidylinositol-3,4,5-trisphosphate REFERENCE PMID:20592731 AUTHORS Moody CA, Laimins LA TITLE Human papillomavirus oncoproteins: pathways to transformation. JOURNAL Nat Rev Cancer 10:550-60 (2010) DOI:10.1038/nrc2886 REFERENCE PMID:25752815 AUTHORS Chen J TITLE Signaling pathways in HPV-associated cancers and therapeutic implications. JOURNAL Rev Med Virol 25 Suppl 1:24-53 (2015) DOI:10.1002/rmv.1823 REFERENCE PMID:26008697 AUTHORS Tummers B, Burg SH TITLE High-risk human papillomavirus targets crossroads in immune signaling. JOURNAL Viruses 7:2485-506 (2015) DOI:10.3390/v7052485 REFERENCE PMID:19684440 AUTHORS Lehoux M, D'Abramo CM, Archambault J TITLE Molecular mechanisms of human papillomavirus-induced carcinogenesis. JOURNAL Public Health Genomics 12:268-80 (2009) DOI:10.1159/000214918 REFERENCE PMID:23164805 AUTHORS Pang CL, Thierry F TITLE Human papillomavirus proteins as prospective therapeutic targets. JOURNAL Microb Pathog 58:55-65 (2013) DOI:10.1016/j.micpath.2012.11.002 REFERENCE PMID:19156753 AUTHORS Yugawa T, Kiyono T TITLE Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. JOURNAL Rev Med Virol 19:97-113 (2009) DOI:10.1002/rmv.605 REFERENCE PMID:17645777 AUTHORS Narisawa-Saito M, Kiyono T TITLE Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. JOURNAL Cancer Sci 98:1505-11 (2007) DOI:10.1111/j.1349-7006.2007.00546.x REFERENCE PMID:11486705 AUTHORS Wolf JK, Ramirez PT. TITLE The molecular biology of cervical cancer. JOURNAL Cancer Invest 19:621-9 (2001) DOI:10.1081/CNV-100104290 REFERENCE PMID:10793105 AUTHORS zur Hausen H TITLE Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. JOURNAL J Natl Cancer Inst 92:690-8 (2000) DOI:10.1093/jnci/92.9.690 REFERENCE PMID:16259056 AUTHORS Kim YT, Zhao M TITLE Aberrant cell cycle regulation in cervical carcinoma. JOURNAL Yonsei Med J 46:597-613 (2005) DOI:10.3349/ymj.2005.46.5.597 REFERENCE PMID:15956361 AUTHORS McCance DJ TITLE Human papillomaviruses and cell signaling. JOURNAL Sci STKE 2005:pe29 (2005) DOI:10.1126/stke.2882005pe29 REFERENCE PMID:15342967 AUTHORS Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T TITLE The role of human papilloma virus in the molecular biology of cervical carcinogenesis. JOURNAL Kobe J Med Sci 50:9-19 (2004) REFERENCE PMID:24316445 AUTHORS Tommasino M TITLE The human papillomavirus family and its role in carcinogenesis. JOURNAL Semin Cancer Biol 26:13-21 (2014) DOI:10.1016/j.semcancer.2013.11.002 REFERENCE PMID:26295406 AUTHORS Bello JO, Nieva LO, Paredes AC, Gonzalez AM, Zavaleta LR, Lizano M TITLE Regulation of the Wnt/beta-Catenin Signaling Pathway by Human Papillomavirus E6 and E7 Oncoproteins. JOURNAL Viruses 7:4734-55 (2015) DOI:10.3390/v7082842 REFERENCE PMID:26289783 AUTHORS Shah M, Anwar MA, Park S, Jafri SS, Choi S TITLE In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response. JOURNAL Sci Rep 5:13446 (2015) DOI:10.1038/srep13446 REFERENCE PMID:26797638 AUTHORS James CD, Roberts S TITLE Viral Interactions with PDZ Domain-Containing Proteins-An Oncogenic Trait? JOURNAL Pathogens 5:8 (2016) DOI:10.3390/pathogens5010008 REFERENCE PMID:26147797 AUTHORS Ganti K, Broniarczyk J, Manoubi W, Massimi P, Mittal S, Pim D, Szalmas A, Thatte J, Thomas M, Tomaic V, Banks L TITLE The Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy. JOURNAL Viruses 7:3530-51 (2015) DOI:10.3390/v7072785 REFERENCE PMID:21954943 AUTHORS Subbaiah VK, Kranjec C, Thomas M, Banks L TITLE PDZ domains: the building blocks regulating tumorigenesis. JOURNAL Biochem J 439:195-205 (2011) DOI:10.1042/BJ20110903 REFERENCE PMID:23175122 AUTHORS Banks L, Pim D, Thomas M TITLE Human tumour viruses and the deregulation of cell polarity in cancer. JOURNAL Nat Rev Cancer 12:877-86 (2012) DOI:10.1038/nrc3400 REFERENCE PMID:19029942 AUTHORS Thomas M, Narayan N, Pim D, Tomaic V, Massimi P, Nagasaka K, Kranjec C, Gammoh N, Banks L TITLE Human papillomaviruses, cervical cancer and cell polarity. JOURNAL Oncogene 27:7018-30 (2008) DOI:10.1038/onc.2008.351 REFERENCE PMID:19901438 AUTHORS Jayshree RS, Sreenivas A, Tessy M, Krishna S TITLE Cell intrinsic & extrinsic factors in cervical carcinogenesis. JOURNAL Indian J Med Res 130:286-95 (2009) REFERENCE PMID:16862386 AUTHORS Garnett TO, Duerksen-Hughes PJ TITLE Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. JOURNAL Arch Virol 151:2321-35 (2006) DOI:10.1007/s00705-006-0821-0 REFERENCE PMID:26022660 AUTHORS Zhang L, Wu J, Ling MT, Zhao L, Zhao KN TITLE The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. JOURNAL Mol Cancer 14:87 (2015) DOI:10.1186/s12943-015-0361-x REFERENCE PMID:22078316 AUTHORS Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G TITLE Papillomavirus E5: the smallest oncoprotein with many functions. JOURNAL Mol Cancer 10:140 (2011) DOI:10.1186/1476-4598-10-140 REFERENCE PMID:11753669 AUTHORS DiMaio D, Mattoon D TITLE Mechanisms of cell transformation by papillomavirus E5 proteins. JOURNAL Oncogene 20:7866-73 (2001) DOI:10.1038/sj.onc.1204915 REFERENCE PMID:22262402 AUTHORS Ganguly N TITLE Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value. JOURNAL Cell Oncol (Dordr) 35:67-76 (2012) DOI:10.1007/s13402-011-0069-x REFERENCE PMID:23731971 AUTHORS DiMaio D, Petti LM TITLE The E5 proteins. JOURNAL Virology 445:99-114 (2013) DOI:10.1016/j.virol.2013.05.006 REFERENCE PMID:23403708 AUTHORS De Marco F TITLE Oxidative stress and HPV carcinogenesis. JOURNAL Viruses 5:708-31 (2013) DOI:10.3390/v5020708 REFERENCE PMID:26643553 AUTHORS Wieringa HW, van der Zee AG, de Vries EG, van Vugt MA TITLE Breaking the DNA damage response to improve cervical cancer treatment. JOURNAL Cancer Treat Rev 42:30-40 (2016) DOI:10.1016/j.ctrv.2015.11.008 REFERENCE PMID:19861444 AUTHORS Chung CH, Gillison ML TITLE Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. JOURNAL Clin Cancer Res 15:6758-62 (2009) DOI:10.1158/1078-0432.CCR-09-0784 REFERENCE PMID:11325599 AUTHORS Koromilas AE, Li S, Matlashewski G TITLE Control of interferon signaling in human papillomavirus infection. JOURNAL Cytokine Growth Factor Rev 12:157-70 (2001) DOI:10.1016/S1359-6101(00)00023-X REFERENCE PMID:10702232 AUTHORS Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ TITLE Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. JOURNAL J Biol Chem 275:6764-9 (2000) DOI:10.1074/jbc.275.10.6764 REFERENCE PMID:22499770 AUTHORS Sandberg A, Lindell G, Kallstrom BN, Branca RM, Danielsson KG, Dahlberg M, Larson B, Forshed J, Lehtio J TITLE Tumor proteomics by multivariate analysis on individual pathway data for characterization of vulvar cancer phenotypes. JOURNAL Mol Cell Proteomics 11:M112.016998 (2012) DOI:10.1074/mcp.M112.016998 REFERENCE PMID:9990017 AUTHORS Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P TITLE Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. JOURNAL Proc Natl Acad Sci U S A 96:1291-6 (1999) DOI:10.1073/pnas.96.4.1291 REFERENCE PMID:15175323 AUTHORS Lu Z, Hu X, Li Y, Zheng L, Zhou Y, Jiang H, Ning T, Basang Z, Zhang C, Ke Y TITLE Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. JOURNAL J Biol Chem 279:35664-70 (2004) DOI:10.1074/jbc.M403385200 REFERENCE PMID:18505829 AUTHORS Xu M, Luo W, Elzi DJ, Grandori C, Galloway DA TITLE NFX1 interacts with mSin3A/histone deacetylase to repress hTERT transcription in keratinocytes. JOURNAL Mol Cell Biol 28:4819-28 (2008) DOI:10.1128/MCB.01969-07 REFERENCE PMID:23536685 AUTHORS Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM TITLE The evolving field of human papillomavirus receptor research: a review of binding and entry. JOURNAL J Virol 87:6062-72 (2013) DOI:10.1128/JVI.00330-13 REL_PATHWAY ko04064 NF-kappa B signaling pathway ko04110 Cell cycle ko04115 p53 signaling pathway ko04150 mTOR signaling pathway ko04151 PI3K-Akt signaling pathway ko04210 Apoptosis ko04310 Wnt signaling pathway ko04330 Notch signaling pathway ko04510 Focal adhesion ko04520 Adherens junction ko04530 Tight junction ko04612 Antigen processing and presentation ko04620 Toll-like receptor signaling pathway ko04630 JAK-STAT signaling pathway ///